BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32402633)

  • 1. Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.
    Luo S; Zhang Y; Yang Y; Zhu S; Liu W; Zhu J; Liang X; Jiang Z; Sun S; Hou X; Xiao Y; Li X
    Gynecol Oncol; 2020 Jul; 158(1):66-76. PubMed ID: 32402633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.
    Norquist BM; Brady MF; Harrell MI; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Burger RA; Tewari KS; Backes F; Mannel RS; Glaser G; Bailey C; Rubin S; Soper J; Lankes HA; Ramirez NC; King MC; Birrer MJ; Swisher EM
    Clin Cancer Res; 2018 Feb; 24(4):777-783. PubMed ID: 29191972
    [No Abstract]   [Full Text] [Related]  

  • 3. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
    Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers.
    Yi Z; Chen M; Sun S; Yang C; Mei Z; Yang H; Xiang Q; Qiu H
    Cancer Innov; 2022 Oct; 1(3):220-228. PubMed ID: 38089758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
    Kang J; D'Andrea AD; Kozono D
    J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
    Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
    Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
    [No Abstract]   [Full Text] [Related]  

  • 8. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
    BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
    Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
    J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Mirza MR; Lindahl G; Mahner S; Redondo A; Fabbro M; Rimel BJ; Herrstedt J; Oza AM; Canzler U; Berek JS; González-Martín A; Follana P; Lord R; Azodi M; Estenson K; Wang Z; Li Y; Gupta D; Matulonis U; Feng B
    Cancer Res Commun; 2022 Nov; 2(11):1436-1444. PubMed ID: 36970052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
    Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM
    Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
    J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between gene expression and mutator phenotype predicts homologous recombination deficiency and outcome in ovarian cancer.
    Lu J; Wu D; Li C; Zhou M; Hao D
    J Mol Med (Berl); 2014 Nov; 92(11):1159-68. PubMed ID: 25062964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
    Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
    Owen DH; Williams TM; Bertino EM; Mo X; Webb A; Schweitzer C; Liu T; Roychowdhury S; Timmers CD; Otterson GA
    Lung Cancer; 2019 Aug; 134():167-173. PubMed ID: 31319977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
    Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer].
    Wang X; Yue J; Kang YK; Gao SL; Yuan P
    Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):787-795. PubMed ID: 37805443
    [No Abstract]   [Full Text] [Related]  

  • 18. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
    Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
    Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer.
    Sohn I; Jung WY; Sung CO
    Gynecol Oncol; 2012 Jul; 126(1):103-8. PubMed ID: 22484402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy.
    Zhang S; Yuan Y; Hao D
    PLoS One; 2014; 9(12):e113169. PubMed ID: 25437005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.